Moderna, Inc. 0A45.IL Stock
Moderna, Inc. Price Chart
Moderna, Inc. 0A45.IL Financial and Trading Overview
Moderna, Inc. stock price | 105.47 USD |
Previous Close | 126.64 USD |
Open | 0 USD |
Bid | 127.44 USD x N/A |
Ask | 133.96 USD x N/A |
Day's Range | 129.89 - 129.89 USD |
52 Week Range | 115.3 - 217.15 USD |
Volume | 342 USD |
Avg. Volume | 13.47K USD |
Market Cap | 49.52B USD |
Beta (5Y Monthly) | 1.697464 |
PE Ratio (TTM) | 11.120719 |
EPS (TTM) | 2.68 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
0A45.IL Valuation Measures
Enterprise Value | 40.97B USD |
Trailing P/E | 11.120719 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 3.2880826 |
Price/Book (mrq) | 2.6442325 |
Enterprise Value/Revenue | 2.721 |
Enterprise Value/EBITDA | 7.918 |
Trading Information
Moderna, Inc. Stock Price History
Beta (5Y Monthly) | 1.697464 |
52-Week Change | 1.11% |
S&P500 52-Week Change | 20.43% |
52 Week High | 217.15 USD |
52 Week Low | 115.3 USD |
50-Day Moving Average | 135.04 USD |
200-Day Moving Average | 153.45 USD |
0A45.IL Share Statistics
Avg. Volume (3 month) | 13.47K USD |
Avg. Daily Volume (10-Days) | 5.49K USD |
Shares Outstanding | 381.21M |
Float | 344.06M |
Short Ratio | N/A |
% Held by Insiders | 9.60% |
% Held by Institutions | 68.32% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 31.76% |
Operating Margin (ttm) | 32.05% |
Gross Margin | 39.81% |
EBITDA Margin | 34.35% |
Management Effectiveness
Return on Assets (ttm) | 11.66% |
Return on Equity (ttm) | 26.62% |
Income Statement
Revenue (ttm) | 15.06B USD |
Revenue Per Share (ttm) | 38.61 USD |
Quarterly Revenue Growth (yoy) | -69.29% |
Gross Profit (ttm) | 10.55B USD |
EBITDA | 5.17B USD |
Net Income Avi to Common (ttm) | 4.78B USD |
Diluted EPS (ttm) | 11.68 |
Quarterly Earnings Growth (yoy) | -97.79% |
Balance Sheet
Total Cash (mrq) | 8.92B USD |
Total Cash Per Share (mrq) | 23.41 USD |
Total Debt (mrq) | 1.11B USD |
Total Debt/Equity (mrq) | 5.87 USD |
Current Ratio (mrq) | 3.464 |
Book Value Per Share (mrq) | 49.122 |
Cash Flow Statement
Operating Cash Flow (ttm) | 993M USD |
Levered Free Cash Flow (ttm) | 541.88M USD |
Profile of Moderna, Inc.
Country | United Kingdom |
State | MA |
City | Cambridge |
Address | 200 Technology Square |
ZIP | 02139 |
Phone | 617 714 6500 |
Website | https://www.modernatx.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 3900 |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Q&A For Moderna, Inc. Stock
What is a current 0A45.IL stock price?
Moderna, Inc. 0A45.IL stock price today per share is 105.47 USD.
How to purchase Moderna, Inc. stock?
You can buy 0A45.IL shares on the IOB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Moderna, Inc.?
The stock symbol or ticker of Moderna, Inc. is 0A45.IL.
Which industry does the Moderna, Inc. company belong to?
The Moderna, Inc. industry is Biotechnology.
How many shares does Moderna, Inc. have in circulation?
The max supply of Moderna, Inc. shares is 486.19M.
What is Moderna, Inc. Price to Earnings Ratio (PE Ratio)?
Moderna, Inc. PE Ratio is 39.35447700 now.
What was Moderna, Inc. earnings per share over the trailing 12 months (TTM)?
Moderna, Inc. EPS is 2.68 USD over the trailing 12 months.
Which sector does the Moderna, Inc. company belong to?
The Moderna, Inc. sector is Healthcare.